Greenberg Traurig Advises OPKO Health on $722M+ Agreement to Sell Select BioReference Health Assets to Labcorp

OPKO Health agreed to sell selected BioReference Health assets to Labcorp for $722 million in cash at closing, subject to an adjustment based on closing business revenues. The agreement includes up to $150 million in additional earnout payments tied to revenue from the 4Kscore Test; the transaction remains subject to regulatory approvals and customary closing conditions.

Analysis

The key valuation question for OPKO is not the headline cash amount but what remains inside BioReference and how proceeds are deployed. A completed sale could reduce operating complexity and provide liquidity, but without the assets’ contribution to revenue, earnings, and cash flow, it is impossible to tell whether OPKO is selling a high- or low-return business. The closing revenue adjustment also leaves some near-term consideration exposed to operating performance; the 4Kscore earnout is contingent, not cash-equivalent value. Verify retained operations, transaction perimeter, taxes, and management’s intended use of proceeds before assigning a balance-sheet or multiple benefit.

For Labcorp, the acquired footprint may improve local access and utilization, but incremental volume only creates value if it can be integrated without disrupting service or requiring substantial investment. It may also sharpen competition with Quest Diagnostics for physician relationships and testing volume. Regulatory approval and closing remain catalysts; the more important 1–3 month signals are detail on the revenue adjustment, integration costs, and whether Labcorp updates its financial outlook. Over 6–18 months, execution and retained customer volumes determine whether scale benefits emerge. A slower close, customer attrition, or weak 4Kscore revenue would impair the seller’s expected proceeds; integration costs or volume losses would challenge the buyer thesis. The press release provides no earnings contribution or pro forma impact, so neither stock has a well-supported directional trade on this disclosure alone.

Key Decisions for Investors

• OPK: Treat the announced consideration as a catalyst to investigate, not as equivalent to realized cash value. Before changing the position, verify the assets retained by BioReference, their financial contribution, the closing revenue adjustment mechanics, taxes, and management’s planned use of proceeds.
• LH: Do not underwrite an earnings accretion thesis from footprint alone. Monitor closing conditions and any subsequent disclosure of acquired revenue, integration costs, customer retention, and guidance impact; these are needed to assess whether the deal adds value.
• No immediate pair trade is warranted from the available information. Reassess after financial contribution and transaction-perimeter details are disclosed; a failed or materially delayed approval process, adverse revenue adjustment, or evidence of customer attrition would weaken the transaction thesis.